Technology | 2009.10.29
Virdante Pharmaceuticals Secures Funding to Improve Antibody-based Therapeutics for Autoimmune and Inflammatory Disorders
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Virdante Pharmaceuticals today announced its debut with the closing of a new financing, management additions and expansion of internal product development programs. Virdante Pharmaceuticals was initially funded in 2008 to develop safer and more effective biopharmaceuticals based on the pioneering research by Jeffrey Ravetch, M.D., Ph.D., of The Rockefeller University. Virdante is incorporating Dr. Ravetch’s “Sialic Switch” technology to improv
For more information, please visit
http://www.businesswire.com/news/home/20091029005183/en
Follow us on
Instagram is adding automatic in-app text translation - The Verge views: 1569
Instagram is adding automatic in-app text translation - The Verge views: 1507